Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Dr. Hira Mian reviews selinexor, talquetamab, and emerging trispecifics shaping the future of multiple myeloma care.
Linvoseltamab drives deep, durable responses in relapsed/refractory multiple myeloma, even in high-risk patients.
Phase III MIDAS trial challenges ASCT’s role in MM, showing extended Isa-KRd may rival transplant in MRD-negative patients.
Real-world study of ide-cel in relapsed/refractory myeloma shows strong efficacy across diverse, complex patients.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
In an era of progress, one of the next goal posts is successful development of trispecifics.
Experts spotlight promising new CAR T-cell and bispecific therapies shaping the future of myeloma treatment.
JNJ-5322 shows 100% response at RP2D in anti-BCMA/GPRC5D–naïve multiple myeloma, according to a phase 1 study.
Daratumumab cuts risk of progression or death by 51% in high-risk smoldering myeloma vs monitoring, AQUILA trial shows.
Thirty-three percent of RRMM patients remain progression free ≥5 years after cilta-cel in CARTITUDE-1.
New CAR T and bispecific therapies are reshaping myeloma care. Here's what the latest data reveals.
The FDA raised concerns about the high rates of ocular toxicity in the DREAMM-7 and DREAMM-8 trials.
The results of the study support use of this agent and give clues on optimal timing and sequencing.
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.